This clinical trial is focused on studying the effects of certain medications on patients with Spontaneous Coronary Artery Dissection (SCAD). SCAD is a condition where a tear forms in one of the blood vessels in the heart, which can lead to heart attacks or other heart-related issues. The study will explore the use of two types of medications: Beta-Blockers and Antiplatelet Agents. Beta-Blockers, such as Metoprolol, Propranolol, Atenolol, Carvedilol, and Bisoprolol, are commonly used to manage heart conditions by slowing down the heart rate and reducing blood pressure. Antiplatelet Agents, including Carbasalate Calcium, Prasugrel, Telmisartan, and Ticagrelor, help prevent blood clots by stopping platelets in the blood from sticking together.

The purpose of this study is to assess how effective these medications are in treating patients with SCAD. Participants in the study will be randomly assigned to receive either the active medication or a placebo. The study will last for up to 12 months, during which participants will take the medication orally. Throughout the study, participants will be monitored for any changes in their condition, and the effects of the medication will be evaluated.

By participating in this study, researchers aim to gather valuable information on the potential benefits and safety of using Beta-Blockers and Antiplatelet Agents in managing SCAD. This research could lead to improved treatment options for individuals affected by this condition. The study will also look at various outcomes, such as the occurrence of heart attacks, strokes, or the need for additional heart procedures, to determine the overall effectiveness of the treatment strategy.